You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光(600673.SH):控股子公司門冬胰島素30注射液藥品註冊申請獲受理
格隆匯 02-19 17:20

格隆匯2月19日丨東陽光(600673.SH)公佈,近日,公司控股子公司東陽光藥(01558.HK)收到了國家藥監局簽發的關於門冬胰島素30注射液的《受理通知書》(受理號:CXSS2100019國)。

門冬胰島素30注射液是一款預混胰島素,該品含30%可溶性門冬胰島素和70%精蛋白門冬胰島素,適用於糖尿病的治療,可臨餐注射,其糖化血紅蛋白(HbA1c)達標率更高,可更好地控制餐後血糖。該注射劑在改善血糖控制、減少低血糖風險、提高依從性以及節約醫療成本方面的優勢明顯,更適合低血糖感知受損(IAH)高危患者。

截至目前,東陽光藥門冬胰島素30注射液已累計研發投入約人民幣9593.29萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account